{"id":"ponatinib-blinatumomab","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"Hypertension"},{"rate":"20-30%","effect":"Headache"},{"rate":"20-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Ponatinib works by inhibiting the BCR-ABL1 tyrosine kinase, which is a protein that is often overactive in certain types of leukemia. Blinatumomab, on the other hand, works by binding to CD19 and CD3, which are proteins found on the surface of B cells, and triggering an immune response against these cells.","oneSentence":"Ponatinib is a tyrosine kinase inhibitor that targets BCR-ABL1, while Blinatumomab is a bispecific monoclonal antibody targeting CD19 and CD3.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:24.308Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia (CML), Acute lymphoblastic leukemia (ALL)"}]},"trialDetails":[{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT03739814","phase":"PHASE2","title":"Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-08","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia","enrollment":84},{"nctId":"NCT03263572","phase":"PHASE2","title":"Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-11-29","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression","enrollment":90},{"nctId":"NCT03147612","phase":"PHASE2","title":"Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-08","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1","enrollment":22},{"nctId":"NCT06860269","phase":"PHASE2, PHASE3","title":"A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-05-06","conditions":"Acute Lymphoblastic Leukemia","enrollment":1200},{"nctId":"NCT07301424","phase":"PHASE2","title":"Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL","status":"NOT_YET_RECRUITING","sponsor":"University of Alberta","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia","enrollment":80},{"nctId":"NCT06061094","phase":"PHASE2","title":"Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT","status":"RECRUITING","sponsor":"Goethe University","startDate":"2023-07-14","conditions":"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","enrollment":220},{"nctId":"NCT04722848","phase":"PHASE3","title":"Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2021-09-08","conditions":"Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL","enrollment":236},{"nctId":"NCT04688983","phase":"PHASE2","title":"Study in Adult Ph-positive ALL","status":"UNKNOWN","sponsor":"Cardiff University","startDate":"2021-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ponatinib + Blinatumomab","genericName":"Ponatinib + Blinatumomab","companyName":"Gruppo Italiano Malattie EMatologiche dell'Adulto","companyId":"gruppo-italiano-malattie-ematologiche-dell-adulto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ponatinib is a tyrosine kinase inhibitor that targets BCR-ABL1, while Blinatumomab is a bispecific monoclonal antibody targeting CD19 and CD3. Used for Chronic myeloid leukemia (CML), Acute lymphoblastic leukemia (ALL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}